Novartis AG plans to ramp up its research in Alzheimer’s disease, a potential $20 billion market lacking a major contender and littered with three high-profile drug failures in the past year alone.

Bayer submitted a regulatory application for its CTEPH candidate, riociguat, in Japan.

Achillion Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-21-2013 03:30 PM

Novartis (NVS) recently announced positive results on Afinitor, from a phase III trial, BOLERO-3.

The medical device maker reported net income of $969 million, or 95 cents a share, a decrease of 2 percent from a year ago.

Merck & Co. posts a mysterious gain, while shares keep climbing for Actavis and Warner Chilcott

Jazz Pharmaceuticals Public Limited Company Presents at UBS Global Healthcare Conference, May-21-2013 09:30 AM

Questcor Pharmaceuticals was a leading decliner within the health care sector, falling $0.40 (-1.1%) to $37.21 on light volume

Onyx Pharmaceuticals was a leading decliner within the drugs industry, falling $1.43 (-1.5%) to $92.91 on average volume

Community Health Systems was a leading decliner within the health services industry, falling $1.08 (-2.4%) to $43.23 on average volume

Amgen was a winner within the health care sector, rising $2.06 (2.0%) to $104.24 on average volume

Specialty drugmaker Biogen Idec said Tuesday it submitted a new injectable multiple sclerosis drug to the Food and Drug Administration for U.S. market approval. The drug, called Plegridy, is intended to ...

XenoPort recently reported disappointing results on arbaclofen placarbil (AP) from a pivotal late-stage study.

By Ransdell Pierson May 21 (Reuters) - A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential ...

Kindred Healthcare Inc. - Analyst/Investor Day

The number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, Dupilumab, compared with those getting a placebo.

Novo Nordisk recently announced positive phase III data on its hemophilia B candidate, N9-GP, from the paradigm 2 study.

Heartware International ( HTWR - Snapshot Report) Has seen analysts pump their estimates higher, giving love to this medical device company love and not heartache. As a Zacks Rank #2 (Buy), it is the Bull of the Day.

The acquisition is expected to be accretive to Actavis' 2014 earnings per share by more than 30%.

New Tracking of a Patient's Radiation Exposure

Tip Puts Lobbyist's Career on Hold

Stefano Pessina, the Man Shaking Up U.S. Pharmacy Distribution

Forget to Take Medicine? These Pills Will Tell Your Doctor

Actavis to Buy Warner Chilcott in $5 Billion Deal

Gene Patents Drive Medical Innovation

In a story May 20 about Pfizer Inc. halting a cancer drug study, The Associated Press erroneously reported the uses of two of the drugmaker's existing cancer medicines. Bosulif is approved for use in certain ...

Express Scripts Holding Company Presents at UBS Global Healthcare Conference, May-21-2013 01:30 PM

DDD: Piper Ups Target to $52 on RPDG Buy

Merck (NYSE:MRK) is trading at unusually high volume Tuesday with 33.2 million shares changing hands. It is currently at two times its average daily volume and trading up $2 (+4.4%).

Elan provided an update on its strategic plans for the future.

Luminex's CEO Presents at UBS Global Healthcare Conference (Transcript)

In the wake of scandals and investigations over manufacturing gaffes, countless product recalls and questionable marketing practices, Johnson & Johnson (NYSE:JNJ) is embarking on a round of corporate soul ...

Actavis's $8.5 billion deal for Warner Chilcott will enhance the New Jersey drugmaker's revenue mix and heighten its profile for future dealmaking.

Seattle Genetics Inc. Presents at UBS Global Healthcare Conference, May-21-2013 11:30 AM

By Ronnie Cohen SAN FRANCISCO, May 21 (Reuters) - Thousands of healthcare workers walked off the job at the University of California's five medical centers on Tuesday, delaying surgeries, diagnostic procedures, ...

Watson Pharmaceuticals (NYSE:WPI) is trading at unusually high volume Tuesday with 2.2 million shares changing hands. It is currently at two times its average daily volume and trading up $3.01 (+2.4%)....

A downgrade from Goldman Sachs takes a bite out of the shares of WellCare Health Plans Inc. Tuesday, as the stock is off nearly 5%.

Medical Properties (NYSE:MPW) hit a new 52-week high Tuesday as it is currently trading at $17.50, above its previous 52-week high of $17.49 with 457,058 shares traded as of 2:26 p.m. ET. Average volume ...

The Dow component leading the way higher looks to be Pfizer (NYSE: PFE ), which is sporting a zero-cent gain to $28.70. Holding back the Dow today is Pfizer (NYSE: PFE ), which is lagging the broader index ...

Warner Chilcott (Nasdaq:WCRX) hit a new 52-week high Tuesday as it is currently trading at $20.53, above its previous 52-week high of $20.51 with 17.4 million shares traded as of 1:45 p.m. ET. Average ...

We downgrade our recommendation on Thoratec to Underperform.

IPO Preview: Portola Pharmaceuticals

Amgen Inc. (AMGN) UBS Global Healthcare Conference Call May 21, 2013 10:00 a.m. ET Executives Joseph P. Miletich - Senior Vice President of Research and Development Analysts Matthew Roden - UBS Presentation ...

Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatide

Athenahealth reported that INTEGRIS Health of Oklahoma will utilize its cloud-based offerings.

WellPoint (NYSE:WLP) hit a new 52-week high Tuesday as it is currently trading at $78.35, above its previous 52-week high of $78.33 with 784,506 shares traded as of 1:16 p.m. ET. Average volume has been ...

Sarepta Therapeutics' CEO Presents at 2013 UBS Global Healthcare Conference (Transcript)

The death toll from the massive tornado that struck the suburbs of Oklahoma City on Monday has been lowered, say reports.